<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04595162</url>
  </required_header>
  <id_info>
    <org_study_id>PGC0005</org_study_id>
    <nct_id>NCT04595162</nct_id>
  </id_info>
  <brief_title>A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL</brief_title>
  <official_title>A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an early, open, single-centered trial. The aim of this study is to evaluate the&#xD;
      safety and tolerance of GC019F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The&#xD;
      study will include 6-12 subjects to receive GC019F therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an early, open, single-centered trial. The major aim of this study is to&#xD;
      evaluate the safety and tolerance of GC019F CAR-T cell immunotherapy in relapsed or&#xD;
      refractory B-ALL. The study will include 6-12 subjects to receive GC019F single infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2035</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events(AE)</measure>
    <time_frame>15 years</time_frame>
    <description>AEs will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except for CRS/ICANS )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAR copies and concentration of GC007F in peripheral blood, bone marrow and CSF</measure>
    <time_frame>2 years</time_frame>
    <description>GC007F CAR copies and cells in peripheral blood, bone marrow and CSF will be measured by qPCR and FCM in 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) and minimal residual disease negative (MRD-) rate of patients who received GC007F infusion</measure>
    <time_frame>2 years</time_frame>
    <description>ORR will be estimated as the percentage of patients who achieved CR or CRi. MRD- rate will be estimated as the percentage of patients who achieved MRD-(blast cells in bone marrow&lt;10^-4 as determined by FCM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR), progression-free survival (PFS), overall survival (OS) of patients who received GC007F infusion</measure>
    <time_frame>15 years</time_frame>
    <description>DOR refers to the time interval from the date when the patient was evaluated as CR/CRi for the first time to the date when the patient was evaluated as disease relapse or death due to any reason. PFS refers to the time interval from the date of GC007F infusion to the date when the patient was evaluated as disease relapse or death due to any reason. OS refers to the time interval from the date of GC007F infusion to the date when the patient died due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of anti-GC007F antibody after infusion</measure>
    <time_frame>2 years</time_frame>
    <description>After GC007F infusion, GC007F antibody in peripheral blood will be measured in 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>CAR-T treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive one dose of GC019F.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC019F</intervention_name>
    <description>GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.</description>
    <arm_group_label>CAR-T treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-70 years;&#xD;
&#xD;
          2. Eastern cooperative oncology group (ECOG) performance status of 0 to 2;&#xD;
&#xD;
          3. Life expectancy≥12 weeks;&#xD;
&#xD;
          4. CD19 tumor expression demonstrated in bone marrow or peripheral blood by flow&#xD;
             cytometry;&#xD;
&#xD;
          5. Relapsed or refractory B- ALL: a) Refractory B- ALL: Fail to achieve a CR after 2&#xD;
             cycles of a standard induction chemotherapy regimen or one-line/multi-line salvage&#xD;
             chemotherapy; b) Relapsed B- ALL: Relapse after remission for the first time in 12&#xD;
             months or relapse after one-line/multi-line salvage chemotherapy; Relapse is defined&#xD;
             as recurrence of primitive cell in peripheral blood or bone marrow(&gt;5%) after&#xD;
             remission; c)Relapse after autologous stem cell transplantation or allogeneic&#xD;
             hematopoietic stem cell transplantation; d)Patients with Philadelphia chromosome&#xD;
             positive(Ph+) ALL were eligible if they were intolerant to or had failed two lines of&#xD;
             tyrosine kinase inhibitor (TKI) therapy, or had t315i mutation.&#xD;
&#xD;
          6. Did not receive hematopoietic stem cell transplantation≤6 months prior to enrollment;&#xD;
&#xD;
          7. Adequate organ function defined as: a) Creatinine clearance (as estimated by Cockcroft&#xD;
             Gault method) &gt;60 mL/min; b) Serum ALT/AST &lt;2.5 ULN; c) Total bilirubin &lt;1.5 ULN&#xD;
             (subjects with Gilbert's syndrome≤3 ULN); d) Cardiac ejection fraction≥50%, no&#xD;
             evidence of clinically significant pericardial effusion as determined by an ECHO; e)&#xD;
             No clinically significant pleural effusion; f) Baseline oxygen saturation &gt;92% on room&#xD;
             air;&#xD;
&#xD;
          8. Females of reproductive age must be in non-lactation period. Females of childbearing&#xD;
             potential must have a negative serum or urine pregnancy test. All subjects must use&#xD;
             medical-approved-contraception (such as intrauterine device and contraceptive drugs)&#xD;
             during the treatment and in 2 years after cell transfusion treatment; Males should&#xD;
             avoid sperm donation;&#xD;
&#xD;
          9. Venous access can be established, peripheral blood mononuclear cells (PBMC) can be&#xD;
             collected in researcher's judgement;&#xD;
&#xD;
         10. The subject agrees to and sign informed consent form;&#xD;
&#xD;
         11. The subject can communicate well with the researcher, is willing and able to comply&#xD;
             with the research plans, and finish the research according to the research rule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Isolated extramedullary leukemia or isolated extramedullary disease relapse;&#xD;
&#xD;
          2. Central nervous system leukemia involved CNS3;&#xD;
&#xD;
          3. Concomitant malignancy other than cured non-melanoma skin cancer or cervical carcinoma&#xD;
             in situ or localized prostate cancer or superficial bladder cancer or ductal carcinoma&#xD;
             in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment&#xD;
             during the 5 years;&#xD;
&#xD;
          4. Any result of the following infectious disease tests is positive: HIV; HCV; HBsAg; or&#xD;
             HBcAb positive with HBV DNA copies positive; TPPA;&#xD;
&#xD;
          5. Live vaccine ≤4 weeks prior to enrollment;&#xD;
&#xD;
          6. For Ph+ ALL, TKI therapy ≤1 week prior to enrollment;&#xD;
&#xD;
          7. History of anti-CD19 therapy or CAR-T or other gene-editing T cell therapy;&#xD;
&#xD;
          8. Presence of ≥ grade 2 acute graft-versus-host disease (GVHD, Glucksberg criteria) or&#xD;
             extensive chronic GVHD (Seattle criteria) that require treatment ≤4 weeks prior to&#xD;
             enrollment, or during the study period the subject is required to receive anti-GCHD&#xD;
             therapy in researcher's judgement;&#xD;
&#xD;
          9. Presence of concomitant disease that require systemic steroids or other immune&#xD;
             suppressive therapy during the study period in researcher's judgement; Allogeneic cell&#xD;
             therapy (such as donor lymphocyte infusion, DLI) ≤4 weeks prior to enrollment;&#xD;
&#xD;
         10. CNS stereotactic radiotherapy ≤4 weeks prior to enrollment;&#xD;
&#xD;
         11. Toxicities related to previous therapy did not relieved to ≤1 grade, except&#xD;
             hematological toxicity and alopecia;&#xD;
&#xD;
         12. Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or&#xD;
             presence of other intolerant conditions, or severe allergic constitution;&#xD;
&#xD;
         13. Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren&#xD;
             syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel&#xD;
             disease, Hashimoto's thyroiditis, hypothyroidism which can be controlled by thyroid&#xD;
             hormone replacement therapy is an exception);&#xD;
&#xD;
         14. For patients that underwent or plan to undergo major surgical operation before CAR-T&#xD;
             treatment, major surgery which required general anesthesia happened ≤4 weeks prior to&#xD;
             enrollment, or did not be fully recovered and clinically stable prior to enrollment,&#xD;
             or be anticipated to undergo major surgical operation which requires general&#xD;
             anesthesia during the study;&#xD;
&#xD;
         15. Took drug from other research≤28 days prior to enrollment;&#xD;
&#xD;
         16. Any unstable cardiovascular diseases happened ≤6 months prior to enrollment, including&#xD;
             but not limited to, unstable angina, myocardial infarction, heart failure (NYHA grade≥&#xD;
             III grade), severe arrhythmia that require drug interference, cardiac&#xD;
             angioplasty/coronary stent implantation/ cardiac bypass surgery ≤6 months prior to&#xD;
             enrollment;&#xD;
&#xD;
         17. Presence of central nervous system (CNS) disease or disease history, including&#xD;
             epilepsy, cerebral ischemia/bleeding, dementia, cerebellar disease, or any autoimmune&#xD;
             diseases that involve CNS;&#xD;
&#xD;
         18. Any other condition that researcher think it is inappropriate for the subject to&#xD;
             anticipate the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongmei Jing, Doctor</last_name>
    <phone>15611908428</phone>
    <email>hongmei_jing@163.com</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

